Docket Number: 037003-0280647 Sient Reference: 1992-30-0029CP1C2 PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re the Application of ANDERSON et al. Group Art Unit: 1644

Application No.: 09/911,703

Examiner: Ronald B. Schwadron

Filed: July 25, 2001

Confirmation No.: 4927

For: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION

ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

TZA Call

Thomas A. Cawley, Jr., Ph.D. Registration Number 40.944

Date: November 21, 2003 PILLSBURY WINTHROP LLP Telephone: (703) 905-2000 Facsimile: (703) 905-2500 P.O. Box 10500

McLean, VA 22102 TAC/JBM:ntb

FORM PTO-1449 (modified) Atty. М# Client Ref. To: U.S. Department of Commerce Dkt. No. (PW FORM PAT-1449) Patent and Trademark Office 0280647 1992-30-0029CP1C2 INFORMATION DISCLOSURE STATEMENT Applicant: ANDERSON et al. BY APPLICANT Appln. No.: 09/911,703 Filing Date: July 25, 2001 Page 1 Date: November 21, 2003 1 Examiner: R. Schwadron Group Art Unit: 1644 U.S. PATENT DOCUMENTS Examiner's Class Document Date Name Sub Filing Initials* Class Date Number MM/YYYY (Family Name of First Inventor) AR 6,183,744 B1 02/2001 GOLDENBERG BR 6,306,393 B1 10/2001 GOLDENBERG CR DR **ER** FR FOREIGN PATENT DOCUMENTS Document Country English Translation Date **Inventor Name** Readily Abstract MM/YYYY Number Available GR HR IR JR **KR** LR OTHER MR Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83. NR Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, Proceedings of ASCO, Vol. 9, p. 271, Abstract No. 1051. OR Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting, p. 852, Abstract No. 622. PR Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 4, No. 1, p. 36. Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, Blood, Vol. 76, No. 10, Abstract No. 1409. Kaminski, et al., "Imaging, Dosimetry, and Radioimunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, Journal of Clinical Oncology, Vol. 10, No. 11, pp.1696-1711. SR TR UR **VR** Examiner Date Considered:

Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not

in conformance and not considered. Include copy of this form with next communication to Applicant.

30398286v1

EXAMINER: